BRAF and melanoma: Later, in a phase III clinical study as a single agent for patients with BRAF V600E- or V600K-mutant melanoma, treatment with trametinib obtained an ORR of 22% and PFS of 4.8 months, compared to an ORR of 8% and a PFS of 1.5 months for the group treated with chemotherapy [136].